D.Fill Medium: A Professional's Guide to Regulatory Status & Market Access

D.Fill Medium is a hyaluronic acid dermal filler manufactured in South Korea by D.Pharm Co., Ltd. As a Korean-origin product, its primary domestic oversight comes from the Korea Food & Drug Administration (KFDA). This signifies compliance with national standards for medical devices.

Furthermore, the manufacturing facilities operate under Good Manufacturing Practice (GMP) protocols. GMP certification is a critical quality assurance standard that ensures products are consistently produced and controlled according to strict quality guidelines. The manufacturer also holds ISO certification, [VERIFY: specific ISO standard, e.g., ISO 13485 for medical devices], which validates its quality management system on an international level. These certifications form the foundation of the product's quality and safety profile for professional use.

For access to the European Union (EU) and European Economic Area (EEA) markets, medical devices like dermal fillers require a CE mark. The CE mark certifies that a product has met the EU's health, safety, and environmental protection requirements. As of this writing, the CE certification status for D.Fill Medium is [VERIFY: D.Fill Medium is/is not CE marked].

If the product is CE marked, it can be legally commercialized within the EU. For the United Kingdom market post-Brexit, the UKCA (UK Conformity Assessed) mark is the equivalent standard. Professionals in the UK should verify if the product carries a valid UKCA mark or if it falls under any transitional arrangements allowing for the continued recognition of the CE mark. Sourcing from a reliable distributor who can provide documentation is key. The full hyaluronic acid dermal filler catalog includes products with verified market access for various regions.

The United States market is regulated by the Food and Drug Administration (FDA). The process for FDA approval for a Class III medical device like a dermal filler is exceptionally rigorous and distinct from KFDA or CE certification. Many high-quality international fillers do not pursue FDA approval due to the extensive clinical trial data and resources required.

Currently, D.Fill Medium is [VERIFY: not approved by the FDA] for sale or use within the United States. This means it cannot be legally marketed or administered by practitioners in the US. Clinics operating in the US should source only FDA-approved fillers to remain compliant with federal regulations. The regulatory landscape often leads clinics to compare different products; a detailed breakdown can be found in our analysis, D.Fill Medium vs. Hyaldew vs. Elasty Plus: A Professional So.

For export markets in the Gulf Cooperation Council (GCC), Latin America (LATAM), and Asia-Pacific (APAC), regulatory requirements are country-specific. Major authorities include the SFDA in Saudi Arabia, ANVISA in Brazil, and the HSA in Singapore. D.Fill Medium may be registered in some of these jurisdictions but not others.

Professional buyers in these regions must conduct due diligence with their local ministry of health or regulatory body to confirm the import and use legality of D.Fill Medium. Often, distributors handle regional registrations. When sourcing through parallel import channels, the responsibility for compliance falls heavily on the importing clinic. It is vital to work with suppliers who understand the nuances of these markets, similar to the protocols outlined in our Hyaldew Non-Lidocaine: A Wholesale Sourcing Guide for Aesthe.

Regardless of your region, verifying the authenticity and compliance of your stock is non-negotiable. When sourcing D.Fill Medium, or other products in its line like D.Fill Hard, clinics should demand specific documentation from their wholesale supplier. This protects your practice and ensures you are using the genuine product.

Key documents include: